Interleukin-12 -- a messenger molecule of immune cells -- was long considered to trigger the development of psoriasis. Now, researchers have shown that interleukin-12 does not actually cause the skin disease but protects against it. This also explains why common psoriasis drugs that block the messenger show insufficient treatment efficacy.